DDInter405 DDInter1341
Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed. It is not known if the drug extends life expectancy. Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated.
Onasemnogene abeparvovec is an adeno-associated virus vector-based gene therapy that has been approved by the FDA in May 2019 for the treatment of infant patients (less than 2 years of age) with spinal muscular atrophy (SMA) and a specific mutation in the survival motor neuron 1 (SMN1) gene. SMA is a rare genetic disease that affects the survival and function of motor neurons, leading to debilitating and often fatal muscle weakness. As there is no cure for SMA, onasemnogene abeparvovec is a disease-modifying agent that decelerates the disease progression, improves motor function, and manages the symptoms. The use and effectiveness of onasemnogene abeparvovec in patients with advanced SMA, such as those with complete paralysis of the limbs and permanent dependence on ventilators, has not been evaluated. Onasemnogene abeparvovec is the first gene therapy that was approved for this indication in the USA. [Nusinersen] is another gene therapy that is currently approved by the FDA for the treatment of SMA in pediatric and adult patients. Developed by AveXis, a Novartis company, onasemnogene abeparvovec is commonly marketed as Zolgensma®, which is available as a single-dose intravenous infusion. Onasemnogene abeparvovec for therapeutic use and marketing is currently being assessed by the EU and an intrathecal formulation of the drug is currently undergoing clinical development in the USA.
Clofarabine {u} (Compound) resembles {v} (Compound) Adenosine monophosphate
Clofarabine {u} (Compound) resembles {v} (Compound) Nelarabine
Clofarabine {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Clofarabine {u} (Compound) treats {v} (Disease) hematologic cancer
Clofarabine {u} (Compound) binds {v} (Gene) DCK
Clofarabine {u} (Compound) upregulates {v} (Gene) FAS
Clofarabine {u} (Compound) is included by {v} (Pharmacologic Class) Nucleic Acid Synthesis Inhibitors
Clofarabine {u} (Compound) downregulates {v} (Gene) ARL6IP1
Clofarabine {u} (Compound) causes {v} (Side Effect) Escherichia bacteraemia
Clofarabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Clofarabine (Compound) resembles Adenosine monophosphate (Compound)
Clofarabine (Compound) resembles Nelarabine (Compound)
Clofarabine may lead to a major life threatening interaction when taken with Cladribine
Clofarabine (Compound) treats hematologic cancer (Disease)
Clofarabine (Compound) binds DCK (Gene)
Clofarabine (Compound) upregulates FAS (Gene)
Clofarabine (Compound) is included by Nucleic Acid Synthesis Inhibitors (Pharmacologic Class)
Clofarabine (Compound) downregulates ARL6IP1 (Gene)
Clofarabine (Compound) causes Escherichia bacteraemia (Side Effect)
Clofarabine may cause a minor interaction that can limit clinical effects when taken with Enoxacin